Syndax Pharmaceuticals Revenue and Competitors

Boston, MA USA

Location

#6613

Growjo Ranking

Biotech

Industry

Estimated Revenue & Valuation

  • Syndax Pharmaceuticals's estimated annual revenue is currently $13.5M per year.(i)
  • Syndax Pharmaceuticals's estimated revenue per employee is $57,489
  • Syndax Pharmaceuticals's total funding is $195M.
  • Syndax Pharmaceuticals's current valuation is $976.3M. (January 2022)

Employee Data

  • Syndax Pharmaceuticals has 235 Employees.(i)
  • Syndax Pharmaceuticals grew their employee count by 63% last year.

Syndax Pharmaceuticals's People

NameTitleEmail/Phone
1
Chief Accounting OfficerReveal Email/Phone
2
VP | VP | Marketing | Sales | TrainingReveal Email/Phone
3
Chief Commercial OfficerReveal Email/Phone
4
Chief People OfficerReveal Email/Phone
5
Chief Commercial Officer (CCO)Reveal Email/Phone
6
VP Clinical OperationsReveal Email/Phone
7
Head Market Analytics and Insights,Reveal Email/Phone
8
Head Payer RelationsReveal Email/Phone
9
VP Information TechnologyReveal Email/Phone
10
General Counsel and SecretaryReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5.2M67-45%$107.3MN/A
#2
$0.3M20%N/AN/A
#3
$5.1M336%N/AN/A
#4
$11.9M77-37%$312.8MN/A
#5
$0.9M60%N/AN/A
#6
$235M300-5%$340.9MN/A
#7
$45.9M237-7%$7.6MN/A
#8
$3.9M5035%N/AN/A
#9
$5.4M353%N/AN/A
#10
$1.6M100%N/AN/A
Add Company

What Is Syndax Pharmaceuticals?

Syndax Pharmaceuticals, Inc., was founded in 2005 to extend and improve the lives of cancer patients by developing and commercializing novel therapies. Our vision is bold—to modify the tumor phenotype, allowing for new therapeutic opportunities that restore or extend the benefit of targeted therapies. Our vision is practical—to develop effective regimens that have broad commercial potential by optimizing features important to patients, physicians, and payers.

keywords:N/A

$195M

Total Funding

235

Number of Employees

$13.5M

Revenue (est)

63%

Employee Growth %

$976.3M

Valuation

N/A

Accelerator

Syndax Pharmaceuticals News

2022-04-20 - Contrasting ProMetic Life Sciences (OTCMKTS:PFSCF) and ...

Syndax Pharmaceuticals has higher revenue and earnings than ProMetic Life Sciences. Insider & Institutional Ownership. 0.1% of ProMetic Life...

2022-04-17 - Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Given ...

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Given Average Rating of “Buy” by Analysts. Posted by admin on Apr 18th, 2022.

2022-04-06 - Syndax Pharmaceuticals: Cash-Rich With 2 Promising Drugs

Syndax Pharmaceuticals (NASDAQ:SNDX) shares appear to be under accumulation with sellers stepping back, and several cash raises have left...

2015-08-24 - Syndax Pharmaceuticals Closes $80M in Series C Funding

Syndax Pharmaceuticals Inc., a Waltham, Massachusetts-based biopharmaceutical company focused on treating cancer, closed $80m in Series C funding. The round was led by Fidelity Management & Research Company and Delos Capital Fund LP led with participation from EcoR1 Capital, OrbiMed, Jennison A ...

2015-08-24 - Syndax Raises $80 Million in Series C Financing

WALTHAM, Mass., August 24, 2015 – Syndax Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing entinostat as a combination therapy in multiple cancer indications, announced today that it has completed an $80 million Series C financing. The financing was led by Fidelity ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$58.3M24120%N/A
#2
$15M25312%N/A
#3
$72.4M259-15%N/A
#4
$39.9M2595%N/A
#5
$52.7M266N/AN/A